OR WAIT null SECS
June 15, 2022
Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
June 14, 2022
Industry must continue research and development to combat the pandemic.
June 13, 2022
Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).
June 08, 2022
Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Survey taken by pharma and CRO executives evaluates attributes of large datasets.
June 06, 2022
Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
May 26, 2022
Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.
May 25, 2022
Its use enables key processes such as early access, regulatory approval, and reimbursement listing.
May 24, 2022
Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.
May 23, 2022
Pharm Exec speaks with Ambrogio about the struggles the industry faces in regard to developing cures for rare cancers, and how Bayer is using precision medicine to meet these challenges.
